355 related articles for article (PubMed ID: 11479205)
21. Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway.
Falck J; Lukas C; Protopopova M; Lukas J; Selivanova G; Bartek J
Oncogene; 2001 Sep; 20(39):5503-10. PubMed ID: 11571648
[TBL] [Abstract][Full Text] [Related]
22. The TP53 gene promoter is not methylated in families suggestive of Li-Fraumeni syndrome with no germline TP53 mutations.
Finkova A; Vazna A; Hrachovina O; Bendova S; Prochazkova K; Sedlacek Z
Cancer Genet Cytogenet; 2009 Aug; 193(1):63-6. PubMed ID: 19602465
[TBL] [Abstract][Full Text] [Related]
23. Familial gastric cancer and Li-Fraumeni syndrome.
Corso G; Pedrazzani C; Marrelli D; Pinto E; Roviello F
Eur J Cancer Care (Engl); 2010 May; 19(3):377-81. PubMed ID: 19674071
[TBL] [Abstract][Full Text] [Related]
24. Germ line BAX alterations are infrequent in Li-Fraumeni syndrome.
Barlow JW; Mous M; Wiley JC; Varley JM; Lozano G; Strong LC; Malkin D
Cancer Epidemiol Biomarkers Prev; 2004 Aug; 13(8):1403-6. PubMed ID: 15298965
[TBL] [Abstract][Full Text] [Related]
25. Increased expression of CHK2 in human gastric carcinomas harboring p53 mutations.
Shigeishi H; Yokozaki H; Oue N; Kuniyasu H; Kondo T; Ishikawa T; Yasui W
Int J Cancer; 2002 May; 99(1):58-62. PubMed ID: 11948492
[TBL] [Abstract][Full Text] [Related]
26. Detection of 11 germline inactivating TP53 mutations and absence of TP63 and HCHK2 mutations in 17 French families with Li-Fraumeni or Li-Fraumeni-like syndrome.
Bougeard G; Limacher JM; Martin C; Charbonnier F; Killian A; Delattre O; Longy M; Jonveaux P; Fricker JP; Stoppa-Lyonnet D; Flaman JM; Frébourg T
J Med Genet; 2001 Apr; 38(4):253-7. PubMed ID: 11370630
[No Abstract] [Full Text] [Related]
27. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families.
Birch JM; Hartley AL; Tricker KJ; Prosser J; Condie A; Kelsey AM; Harris M; Jones PH; Binchy A; Crowther D
Cancer Res; 1994 Mar; 54(5):1298-304. PubMed ID: 8118819
[TBL] [Abstract][Full Text] [Related]
28. A germ line mutation in exon 5 of the p53 gene in an extended cancer family.
Law JC; Strong LC; Chidambaram A; Ferrell RE
Cancer Res; 1991 Dec; 51(23 Pt 1):6385-7. PubMed ID: 1933902
[TBL] [Abstract][Full Text] [Related]
29. Association of germline or somatic TP53 missense mutation with oncogene amplification in tumors developed in patients with Li-Fraumeni or Li-Fraumeni-like syndrome.
Sugawara W; Arai Y; Kasai F; Fujiwara Y; Haruta M; Hosaka R; Nishida K; Kurosumi M; Kobayashi Y; Akagi K; Kaneko Y
Genes Chromosomes Cancer; 2011 Jul; 50(7):535-45. PubMed ID: 21484931
[TBL] [Abstract][Full Text] [Related]
30. The profile and contribution of rare germline copy number variants to cancer risk in Li-Fraumeni patients negative for TP53 mutations.
Silva AG; Krepischi AC; Pearson PL; Hainaut P; Rosenberg C; Achatz MI
Orphanet J Rare Dis; 2014 Apr; 9():63. PubMed ID: 24775443
[TBL] [Abstract][Full Text] [Related]
31. p53 germline mutations in Li-Fraumeni syndrome.
Santibáñez-Koref MF; Birch JM; Hartley AL; Jones PH; Craft AW; Eden T; Crowther D; Kelsey AM; Harris M
Lancet; 1991 Dec; 338(8781):1490-1. PubMed ID: 1683921
[TBL] [Abstract][Full Text] [Related]
32. Exclusion of a p53 germline mutation in a classic Li-Fraumeni syndrome family.
Evans SC; Mims B; McMasters KM; Foster CJ; deAndrade M; Amos CI; Strong LC; Lozano G
Hum Genet; 1998 Jun; 102(6):681-6. PubMed ID: 9703430
[TBL] [Abstract][Full Text] [Related]
33. Younger age of cancer initiation is associated with shorter telomere length in Li-Fraumeni syndrome.
Tabori U; Nanda S; Druker H; Lees J; Malkin D
Cancer Res; 2007 Feb; 67(4):1415-8. PubMed ID: 17308077
[TBL] [Abstract][Full Text] [Related]
34. Characterization of tumor-associated Chk2 mutations.
Wu X; Webster SR; Chen J
J Biol Chem; 2001 Jan; 276(4):2971-4. PubMed ID: 11053450
[TBL] [Abstract][Full Text] [Related]
35. The Li-Fraumeni syndrome: an inherited susceptibility to cancer.
Evans SC; Lozano G
Mol Med Today; 1997 Sep; 3(9):390-5. PubMed ID: 9302689
[TBL] [Abstract][Full Text] [Related]
36. Detection of novel germ-line p53 mutations in diverse-cancer-prone families identified by selecting patients with childhood adrenocortical carcinoma.
Sameshima Y; Tsunematsu Y; Watanabe S; Tsukamoto T; Kawa-ha K; Hirata Y; Mizoguchi H; Sugimura T; Terada M; Yokota J
J Natl Cancer Inst; 1992 May; 84(9):703-7. PubMed ID: 1569604
[TBL] [Abstract][Full Text] [Related]
37. Li-Fraumeni syndrome: the genetics and treatment considerations for the sarcoma and associated neoplasms.
Upton B; Chu Q; Li BD
Surg Oncol Clin N Am; 2009 Jan; 18(1):145-56, ix. PubMed ID: 19056046
[TBL] [Abstract][Full Text] [Related]
38. Analysis of Li-Fraumeni syndrome and Li-Fraumeni-like families for germline mutations in Bcl10.
Stone JG; Eeles RA; Sodha N; Murday V; Sheriden E; Houlston RS
Cancer Lett; 1999 Dec; 147(1-2):181-5. PubMed ID: 10660104
[TBL] [Abstract][Full Text] [Related]
39. DNA damage-associated dysregulation of the cell cycle and apoptosis control in cells with germ-line p53 mutation.
Goi K; Takagi M; Iwata S; Delia D; Asada M; Donghi R; Tsunematsu Y; Nakazawa S; Yamamoto H; Yokota J; Tamura K; Saeki Y; Utsunomiya J; Takahashi T; Ueda R; Ishioka C; Eguchi M; Kamata N; Mizutani S
Cancer Res; 1997 May; 57(10):1895-902. PubMed ID: 9157982
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of early onset colorectal cancer in 397 patients with classic Li-Fraumeni syndrome.
Wong P; Verselis SJ; Garber JE; Schneider K; DiGianni L; Stockwell DH; Li FP; Syngal S
Gastroenterology; 2006 Jan; 130(1):73-9. PubMed ID: 16401470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
